Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31855317)

  • 1. Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor.
    Hirabayashi K; Tajiri T; Bosch DE; Morimachi M; Miyaoka M; Inomoto C; Nakamura N; Yeh MM
    Pathol Int; 2020 Feb; 70(2):84-91. PubMed ID: 31855317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma.
    Yamada M; Hirabayashi K; Kawanishi A; Hadano A; Takanashi Y; Izumi H; Kawaguchi Y; Mine T; Nakamura N; Nakagohri T
    Surg Today; 2018 May; 48(5):510-516. PubMed ID: 29256146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
    Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
    Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
    Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
    Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis.
    Izumi H; Hirabayashi K; Nakamura N; Nakagohri T
    Surg Today; 2015 Apr; 45(4):487-94. PubMed ID: 25690753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
    Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
    Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nectin-1 Expression in Colorectal Cancer: Is There a Group of Patients with High Risk for Early Disease Recurrence?
    Tampakis A; Tampaki EC; Nonni A; Droeser R; Posabella A; Tsourouflis G; Kontzoglou K; Patsouris E; von Flüe M; Kouraklis G
    Oncology; 2019; 96(6):318-325. PubMed ID: 30917374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD47 expression and CD163
    Imam R; Chang Q; Black M; Yu C; Cao W
    BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
    Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
    Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
    Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
    Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.
    Aysal A; Agalar C; Egeli T; Unek T; Oztop I; Obuz F; Sagol O
    Endocr Pathol; 2021 Dec; 32(4):461-472. PubMed ID: 34283399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor.
    Lee YS; Kim H; Kim HW; Lee JC; Paik KH; Kang J; Kim J; Yoon YS; Han HS; Sohn I; Cho J; Hwang JH
    Medicine (Baltimore); 2015 Dec; 94(50):e2224. PubMed ID: 26683934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
    Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
    Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.